Please note: The information displayed on this page might be outdated.
Rexgenero Ltd.: Rexgenero is a clinical-stage regenerative medicine company developing innovative cell-based therapies targeting serious diseases with unmet medical needs. The company’s lead candidate, REX-001, is a highly innovative autologous cell therapy that is being studied in a Phase III clinical program in patients with critical limb ischemia (CLI) with diabetes, a poorly treated disease with a high risk of amputation and death. REX-001 has been shown to be effective by offering the potential to increase the quality of life of CLI patients by reducing pain, alleviating ulcers, increasing mobility, improving sleep and reducing the need for amputation. Rexgenero is developing REX-001 in a range of indications and, pending approval, intends to launch and market this specialty product in major territories.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe, United Kingdom
Clinical Stage
Phase III
Disease Space
Cardiovascular, Diabetes
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Private
Therapeutic Modalities
Cell Therapy
Website:
Profiles:
Address:
45 Pont Street
London, England SW1X 0BD
United Kingdom

Company Participants at European Biotech Investor Day 2019

  • Edwin Wagena, COO
  • Joe Dupere, Dr, CEO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.